Are natriuretic peptides a reliable marker for mortality in ESRD patients

Nephrology Dialysis Transplantation

Volumn 25, Issue 2, 2010, Pages 347-349

  Locatelli, Francesco ^a   Vigan, Sara ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

Cardiovascular mortality; Fluid overload; Natriuretic peptides

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE;

CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MORTALITY; NOTE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RELIABILITY;

BIOLOGICAL MARKERS; HUMANS; KIDNEY FAILURE, CHRONIC; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDES; PEPTIDE FRAGMENTS; REPRODUCIBILITY OF RESULTS;

EID: 75649112997     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp606     Document Type: Note

References (20)

1. European Society of Cardiology; Heart Failure Association of the ESC (HFA); European Society of Intensive Care Medicine (ESICM)Dickstein K et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008; 10: 933-989
2. Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of CardiologyDickstein K, Cohen-Solal A et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008 Oct; 29: 2388-2442
3. London GM, Marchais SJ, Metivier F et al. Cardiovascular risk in endstage renal disease: vascular aspects. Nephrol Dial Transplant 2000; 15: 97-104
4. Law YM, Hoyer AW, Reller MD et al. Accuracy of plasma B-type natriuretic peptide to diagnose significant cardiovascular disease in children: the better not pout children! study. J Am Coll Cardiol 2009; 54: 1467-1475
5. Korenstein D, Wisnivesky JP, Wyer P et al. The utility of B-type natriuretic peptide in the diagnosis of heart failure in the emergency department: a systematic review. BMC Emerg Med 2007; 7: 6
6. Mallamaci F, Tripepi G, Cutrupi S et al. Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and my-ocardiopathy in patients with ESRD. Kidney Int 2005; 67: 2330-2337
7. Paniagua R, Ventura MD, Avila-D́iaz M et al. NT-proBNP, fluid volume overload and dialysis modality are independent predictors of mortality in ESRD patients. Nephrol Dial Transplant 2010; 25: 551-557
8. Vickery S, Price CP, John RI et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 2005; 46: 610-620
9. Haug C, Metzele A, Steffgen J et al. Changes in brain natriuretic peptide and atrial natriuretic peptide plasma concentrations during hemodialysis in patients with chronic renal failure. Horm Metab Res 1994; 26: 246-249
10. Gangji AS, Helal BA, Churchill DN et al. Association between N-terminal propeptide B-type natriuretic peptide and markers of hyper-volemia. Perit Dial Int 2008; 28: 308-311
11. Enia G, Mallamaci F, Benedetto FA et al. Long-term CAPD patients are volume expanded and display more severe left ventricular hypertrophy than haemodialysis patients. Nephrol Dial Transplant 2001; 16: 1459-1464
12. Paniagua R, Amato D, Vonesh E et al. Predictive value of natriuretic peptides in patients on peritoneal dialysis: results from the ADEMEX trial. Clin J Am Soc Nephrol 2008; 3: 407-415
13. Schleiffer T, Nagel D, Franz H et al. Endothelin and atrial na-triuretic peptide in non-insulin-dependent diabetic versus nondia-betic patients on chronic hemodialysis. Ren Fail 1994; 16: 747-758
14. Clerico A, Recchia FA, Passino C et al. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am J Physiol Heart Circ Physiol 2006; 290: H17-H29
15. Günal AI, Ilkay E, Kirciman E et al. Blood pressure control and left ventricular hypertrophy in long-term CAPD and hemodialysis patients: a cross-sectional study. Perit Dial Int 2003; 23: 563-567
16. Struijk DG. Volume status in CAPD and APD: does treatment modality matter anDis more always better? Perit Dial Int 2007; 27: 641-644
17. Rodriguez-Carmona A, Pérez-Fontán M, Garca-Naveiro R et al. Compared time profiles of ultrafiltration, sodium removal, and renal function in incident CAPD and automated peritoneal dialysis patients. Am J Kidney Dis 2004; 44: 132-145
18. Johnson DW, Dent H, Hawley CM et al. Association of dialysis modality and cardiovascular mortality in incident dialysis patients. Clin J Am Soc Nephrol 2009; 4: 1620-1628
19. Locatelli F, Marcelli D, Conte F et al. Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease. J Am Soc Nephrol 2001; 12: 2411-2417
20. Foley RN, Parfrey PS, Harnett JD et al. Mode of dialysis therapy and mortality in end-stage renal disease. J Am Soc Nephrol 1998; 9: 267-276